Unraveling the mechanism of curcumin in coronary slow flow phenomenon through network pharmacology and molecular docking
Open Access
- 24 December 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 44551
Abstract
The coronary slow flow phenomenon (CSFP) is associated with an increased risk of adverse cardiovascular events, yet standardized treatment is lacking. Curcumin, a natural compound, has shown potential in alleviating angina and improving metabolic risk factors in CSFP, but its underlying molecular mechanisms remain unclear. This study employed an integrated computational strategy. Network pharmacology was used to identify potential targets of curcumin and CSFP from public databases, and common targets were identified. Functional enrichment analysis was performed on the common targets, and a protein-protein interaction network was constructed. Core targets were identified using MCODE and CytoHubba plugins in Cytoscape. Molecular docking evaluated the binding modes and affinities of curcumin with the core targets, while molecular dynamics simulations and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculations validated the stability and binding free energies of the complexes. A total of 120 predicted targets of curcumin and 435 CSFP-related targets were identified, yielding 19 common targets. Functional enrichment analysis revealed that curcumin may treat CSFP by modulating inflammatory response, vascular function, cell migration, proliferation, apoptosis, and oxidative stress. These targets were associated with key signaling pathways, including NF-κB, TNF, and HIF-1. Network analysis and topological algorithms identified five core targets: EGFR, ICAM1, NFKB1, PTGS2, and STAT3. Molecular docking results demonstrated that curcumin exhibited excellent binding affinity with all core targets. Molecular dynamics simulations confirmed that the curcumin-core target complexes remained structurally stable during the 100 ns simulation, and MM/GBSA calculations indicated significantly negative binding free energies, suggesting strong binding driving forces. Curcumin may exert therapeutic effects on CSFP through a multi-target mechanism, primarily by interacting with key proteins including EGFR, ICAM1, NFKB1, PTGS2, and STAT3, thereby regulating the NF-κB, TNF, and HIF-1 signaling pathways. This study provides a theoretical foundation for the application of curcumin in CSFP treatment, though further experimental validation is required.Keywords
Funding Information
- Jiangsu Province Postgraduate Research and Practice Innovation Program (SJCX24_1035)
This publication has 132 references indexed in Scilit:
- Pathogenic and clinical significance of inflammation-associated MicroRNAs in cardiovascular diseasesMolecular Biology Reports, 2025
- Nanocurcumin restores aberrant miRNA expression profile in multiple sclerosis, randomized, double‐blind, placebo‐controlled trialJournal of Cellular Physiology, 2018
- Role of TLR4 and miR‐155 in peripheral blood mononuclear cell‐mediated inflammatory reaction in coronary slow flow and coronary arteriosclerosis patientsJournal of Clinical Laboratory Analysis, 2017
- The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence AnalysesCurrent Protocols in Bioinformatics, 2016
- TargetNet: a web service for predicting potential drug–target interaction profiling via multi-target SAR modelsJournal of Computer-Aided Molecular Design, 2016
- Mutational Analysis on Membrane Associated Transporter Protein (MATP) and Their Structural Consequences in Oculocutaeous Albinism Type 4 (OCA4)—A Molecular Dynamics ApproachJournal of Cellular Biochemistry, 2016
- Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitroInflammation Research, 2011
- The effects of perindopril on QT duration and dispersion in patients with coronary slow flowHeart and Vessels, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Effects of Atorvastatin on Coronary Flow Reserve in Patients with Slow Coronary FlowClinical Cardiology, 2007